{"id":3322,"date":"2015-11-12T16:32:47","date_gmt":"2015-11-12T21:32:47","guid":{"rendered":"http:\/\/52.229.122.34\/en\/?p=3322"},"modified":"2017-04-03T11:13:20","modified_gmt":"2017-04-03T15:13:20","slug":"personalized-anti-nausea-therapy-better-for-cancer-patients-ottawa-researchers","status":"publish","type":"post","link":"https:\/\/www.ottawahospital.on.ca\/en\/newsroom\/personalized-anti-nausea-therapy-better-for-cancer-patients-ottawa-researchers\/","title":{"rendered":"Personalized anti-nausea therapy better for cancer patients, Ottawa researchers"},"content":{"rendered":"

World-first trial published in<\/em> JAMA-Oncology shows younger patients, women, those with history of either pregnancy-associated morning sickness or travel sickness, lower alcohol consumption, at greater risk of nausea and vomiting<\/em><\/p>\n

November 12, 2015<\/strong> \u2013 <\/strong>A new research study led by Dr. Mark Clemons<\/a>, oncologist and associate cancer research scientist at The Ottawa Hospital, has shown that a personalized approach to treating one of the most expected side-effects of chemotherapy is far more effective than the existing \u201cone size fits all\u201d set of guidelines. The randomized trial is published in the November 12 issue of JAMA-Oncology<\/em>.<\/p>\n

Nausea and vomiting are among the most feared side-effects of chemotherapy for cancer patients, and in some cases the symptoms can be so debilitating that patients stop treatment. To date, physicians have treated these side-effects with a range of anti-nausea drugs, following a set of set of established guidelines.<\/p>\n

\u201cUnfortunately, these guidelines don\u2019t take into account the personal factors that put patients at higher risk of nausea and vomiting,\u201d said Dr. Clemons, who is also an associate professor of medicine at the University of Ottawa. \u00a0\u00a0His study included 324 breast cancer patients receiving chemotherapy at The Ottawa Hospital and the Irving Greenburg Cancer Centre, . The study demonstrated that when personal risk factors for chemotherapy induced nausea and vomiting (e.g. age under\u00a0 40, those with a history of \u00a0pregnancy-associated morning sickness or travel sickness, or those with lower alcohol consumption) are taken into account when prescribing anti-emetic medications then nausea and vomiting control was significantly improved, when compared with standard physician choice of antiemetics.<\/p>\n

\u201cThis is the first time it\u2019s been shown anywhere in the world that using personal risk factors significantly improves nausea and vomiting control,\u201d explained Dr. Clemons. \u201cAnti-nausea drugs potentially have their own side-effects, and it\u2019s very expensive for the healthcare system to simply give them to every patient regardless of effectiveness. We think these findings can lead to a much better, much kinder, much gentler way of treating cancer patients.\u201d<\/p>\n

The approach is also important because, some patients at particularly high risk still had poor control of nausea and vomiting despite \u201coptimal\u201d antiemetic prescribing. For these patients new treatment strategies need to be developed. On the other hand it is very likely that patients at low risk do not require all the anti-sickness drugs currently recommended.<\/p>\n

\u201cThese results are very straightforward, but they challenge the dogma of the way the guidelines are written,\u201d Dr. Clemons said. \u201cIt\u2019s very easy to simply follow a guideline. Now we\u2019re suggesting that physicians just ask their patients a few key questions first.\u201d<\/p>\n

Study Title: <\/strong>\u201cA Randomized Trial Comparing Risk Model Guided Antiemetic Prophylaxis to Physician\u2019s Choice in Patients Receiving Chemotherapy for Early Stage Breast Cancer\u201d<\/p>\n

Co-authors: <\/strong>Mark Clemons MD, Nathaniel Bouganim MD, Stephanie Smith BA, Sasha Mazzarello BSc, Lisa Vandermeer MSc, Roanne Segal MD, Susan Dent MD, Stan Gertler MD, Xinni Song MD, Paul Wheatley-Price MD, George Dranitsaris PhD<\/p>\n

Funding: <\/strong>Canadian Breast Cancer Foundation, The Ottawa Hospital Foundation<\/p>\n

About The Ottawa Hospital
\n<\/strong>The Ottawa Hospital is one of Canada\u2019s largest learning and research hospitals with over 1,100 beds, approximately 12,000 staff and an annual budget of over $1.2 billion. Our focus on research and learning helps us develop new and innovative ways to treat patients and improve care. As a multi-campus hospital, affiliated with the University of Ottawa, we deliver specialized care to the Eastern Ontario region, but our techniques and research discoveries are adopted around the world. We engage the community at all levels to support our vision for better patient care.<\/p>\n

The University of Ottawa\u2014A crossroads of cultures and ideas<\/strong>
\nThe University of Ottawa is home to over 50,000 students, faculty and staff, who live, work and study in both French and English. Our campus is a crossroads of cultures and ideas, where bold minds come together to inspire game-changing ideas. We are one of Canada\u2019s top 10 research universities\u2014our professors and researchers explore new approaches to today\u2019s challenges. One of a handful of Canadian universities ranked among the top 200 in the world, we attract exceptional thinkers and welcome diverse perspectives from across the globe.<\/p>\n

Media Contacts<\/strong><\/p>\n

Mark Shainblum
\nMedia Relations Officer
\nThe Ottawa Hospital
\nmshainblum@toh.ca<\/a>
\nDirect line: 613-737-8460
\nor 613-737-8899, 78460<\/p>\n

Jennifer Ganton
\nDirector, Communications and Public Relations
\nOttawa Hospital Research Institute
\njganton@ohri.ca<\/a>
\nOffice: 613-798-5555 x 73325
\nCell: 613-614-5253<\/p>\n","protected":false},"excerpt":{"rendered":"

World-first trial published in JAMA-Oncology shows younger patients, women, those with history of either pregnancy-associated morning sickness or travel sickness, lower alcohol consumption, at greater risk of nausea and vomiting November 12, 2015 \u2013 A new research study led by Dr. Mark Clemons, oncologist and associate cancer research scientist at The Ottawa Hospital, has shown […]<\/p>\n","protected":false},"author":25,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[11],"tags":[],"class_list":["post-3322","post","type-post","status-publish","format-standard","hentry","category-newsroom"],"acf":[],"wps_subtitle":"","_links":{"self":[{"href":"https:\/\/www.ottawahospital.on.ca\/en\/wp-json\/wp\/v2\/posts\/3322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ottawahospital.on.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ottawahospital.on.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ottawahospital.on.ca\/en\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ottawahospital.on.ca\/en\/wp-json\/wp\/v2\/comments?post=3322"}],"version-history":[{"count":0,"href":"https:\/\/www.ottawahospital.on.ca\/en\/wp-json\/wp\/v2\/posts\/3322\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ottawahospital.on.ca\/en\/wp-json\/wp\/v2\/media?parent=3322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ottawahospital.on.ca\/en\/wp-json\/wp\/v2\/categories?post=3322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ottawahospital.on.ca\/en\/wp-json\/wp\/v2\/tags?post=3322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}